

PCORnet® Population Insights Report

Characteristics of the Patient Population with Menopausal Conditions Receiving Health Care Services Across PCORnet® Clinical Research Networks in 2024

Rationale for Network Query of PCORnet® Data Resources:

This report characterizes the population of patients with diagnosis codes for menopausal conditions reflected in their medical record and encounters in a health care setting across PCORnet® between January 1 – December 31, 2024.

The report aligns with the Patient-Centered Outcomes Research Institute's® (PCORI®) strategic goal to demonstrate ways PCORnet can be used to address national-scale patient-centered comparative clinical effectiveness research (CER) questions. The results in this report may support planning for future patient-centered CER using PCORnet on the topic of menopause.

Background on PCORnet®:

PCORnet is a large, distributed “network of networks” funded by PCORI to improve the nation’s capacity to efficiently conduct health research, particularly patient-centered CER.

The unique federated architecture of the network enables network sites to query clinical encounter data to identify patients and contact them for recruitment in research studies (with the appropriate regulatory and legal agreements). PCORnet has been used to conduct more than 300 studies, including pragmatic trials, observational research, and data science studies. [PCORnet® Population Insights Reports](#) are created to provide descriptive insights into the feasibility of research questions and the potential to recruit patients for future research using PCORnet.

At the time of this report, PCORnet® Network Partners include eight PCORnet® Clinical Research Networks (CRNs) with 78 partner sites in addition to Patient Partners and the Coordinating Center for PCORnet®. Collectively, these sites are connected to more than 50 million people in the United States and include large academic health systems, hospitals, federally qualified health centers, and community clinics.

For more information on the structure and governance of PCORnet, please see the [PCORnet® Playbook](#).

Population Insights Report Description:

This report describes the results of a data query of the patient population with at least 1 face-to-face encounter and a recorded diagnosis code (e.g., ICD-10) at a health care setting across PCORnet between January 1 – December 31, 2024. The query used a 5-year “look-back” period between January 1, 2020 – December 31, 2024, to identify patients with diagnosis codes for menopausal conditions reflected in the electronic health record. The query results will enhance public awareness of the population of patients with menopausal conditions as well as utilization of health care services by these patients across sites participating in PCORnet that potentially would be available for future health care research.

Data Query Methodology and Criteria:

The Coordinating Center collaborated with PCORI to develop the specifications and criteria for this data query. Collaborators developed a comprehensive list of diagnosis codes related to menopause to be included in this query. The query identified demographic and geographic characteristics of the referenced patient population with at least 1 face-to-face encounter at a site participating in PCORnet during the 1-year query period (January 1 – December 31, 2024). From this patient population, the query characterized patients who had a diagnosis code for any menopause conditions in their electronic health record within a 5-year period (January 1, 2020 – December 31, 2024). The data query also described additional co-occurring conditions, medications, procedures, and utilization of health care settings for this patient group.

Additional methods and information used to specify the query and define the cohorts are available upon request by emailing frontdoor@pcornet.org.

The Coordinating Center programmed and distributed this data query to 75 partners in PCORnet.

Population Insights Report Results:

Seventy-five (75) PCORnet partners contributed data to this report, reflecting the experience of patients who received health care services across sites participating in PCORnet during a 1-year period (January 1 – December 31, 2024).

Results of the query are provided in tables referenced below:

- **Table 1.** Demographic characteristics of the patient population with menopausal conditions receiving health care services across sites participating in PCORnet between January 1, 2024 – December 31, 2024.
- **Table 2.** Care setting and geographic characteristics for patients with a diagnosis code for menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2024 – December 31, 2024.
- **Table 3.** Chronic conditions, procedures, and medication prescribing for patients with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a recorded diagnosis code for a menopausal condition between January 1, 2020 – December 31, 2024.
- **Table 4.** Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2024 – December 31, 2024, for anti-hypertensives, hormonal therapies, selective serotonin reuptake inhibitors (SSRIs), GLP-1 medications, and osteoporosis medications prescribed in 2024.
- **Table 5.** Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2024 – December 31, 2024, for sleep medications, medications for urinary incontinence, serotonin and norepinephrine reuptake inhibitors (SNRIs), medications for hot flashes, and weight-loss medications prescribed in 2024.
- **Table 6.** Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet between January 1, 2024 – December 31, 2024, for selected diagnostic testing, surgeries, and behavioral health interventions delivered in 2024.

Limitations:

Data presented are descriptive and derived from diagnosis and procedure codes collected in the electronic health record (EHR) during health care encounters. Rows and percentages may not add up to a total due to missing values and/or if counts are less than 11. If counts are between 1-10, then they are reported as “-” to protect patient privacy and risk of identification from aggregate values as outlined in the [Data Privacy Statement for PCORnet®](#).

No inferential analyses were conducted to compare populations or test hypotheses, as these are descriptive data only. Limitations with any EHR data analysis are applicable to this data, including the possibility for misclassification due to imperfect algorithms and lack of consistent definition of enrollment to define cohorts, in addition to limitations associated with processes to collect clinical data during health care encounters, including collection of demographic information. Data should be interpreted with these limitations in mind.

To ensure PCORnet data resources are of high quality for research and to mitigate the limitations above, all PCORnet-accessible data resources undergo [rigorous quality curation](#) and screening as part of quarterly coordinated data quality assessment. For more information on data curation activities and strategies to improve data quality for PCORnet, please contact frontdoor@pcornet.org.

Disclaimer:

PCORnet® is intended to improve the nation’s capacity to efficiently conduct patient-centered health research, particularly CER, by providing a large, highly representative network of health data, research expertise, and patient insights. PCORnet has been developed with funding from the Patient-Centered Outcomes Research Institute® (PCORI®).

Network queries that return only aggregate or limited data sets are covered by [the PCORnet® Master Data Sharing Agreement](#) (version 5.0), and site-level blanket Institutional Review Board approvals.

The statements presented in this report do not necessarily represent the views of PCORI or other organizations participating in, collaborating with, or funding PCORnet.

For questions, comments, or suggestions related to this PCORnet® Front Door query or other PCORnet queries, please contact frontdoor@pcornet.org.

Tables

Table 1. Demographic characteristics of the patient population with menopausal conditions receiving health care services across sites participating in PCORnet® between January 1, 2024 – December 31, 2024.^{1, 2}

	Total Patients		Females		Females with Menopausal Conditions		Asymptomatic Menopause ⁴		Menopausal and Other Perimenopausal Disorders ⁴		Excess Premenopausal Bleeding ⁴		Post-procedure Ovarian Failure ⁴		Premature Menopause ⁴	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	1,486,534	54.8	1,467,175	54.1	71,232	2.6	31,723	1.2	30,557	1.1
MEAN AGE (SD)	41.1 (± 22.9)		42.0 (± 22.4)		64.4 (± 12.0)		68.8 (± 9.8)		61.4 (± 11.6)		45.4 (± 9.8)		52.9 (± 12.1)		54.3 (± 11.7)	
AGE																
Children 0-9	6,904,527	13.7	3,256,539	11.5	1,898	0.1	745	0.1	1,111	0.1	58	0.1	13	<0.1	27	0.1
Children 10-19	6,202,107	12.3	3,150,721	11.2	4,009	0.1	712	<0.1	1,381	0.1	1,719	2.4	183	0.6	74	0.2
Adults 20-34	8,066,110	16.0	5,082,956	18.0	23,721	0.9	3,053	0.2	11,476	0.8	7,946	11.2	1,390	4.4	907	3.0
Adults 35-54	11,548,474	23.0	6,898,408	24.5	572,791	21.1	121,431	8.2	439,836	30.0	51,958	72.9	17,742	55.9	16,296	53.3
Adults 55-64	6,319,268	12.6	3,525,577	12.5	662,016	24.4	293,455	19.7	452,111	30.8	8,581	12.0	6,522	20.6	6,439	21.1
Adults 65-74	6,236,732	12.4	3,435,779	12.2	885,785	32.7	658,658	44.3	347,900	23.7	598	0.8	3,881	12.2	4,633	15.2
Adults 75+	5,008,399	10.0	2,858,223	10.1	559,989	20.7	408,480	27.5	213,360	14.5	372	0.5	1,992	6.3	2,181	7.1
SEX																
Female	28,208,203	56.1	28,208,203	100	2,710,209	100	1,486,534	100	1,467,175	100	71,232	100	31,723	100	30,557	100
Male	22,056,069	43.9	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Unknown	15,393	<0.1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Missing ³	5,952	<0.1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
RACE																
White	30,402,190	60.5	16,961,841	60.1	1,939,159	71.6	1,084,879	73.0	1,048,997	71.5	41,320	58.0	23,848	75.2	20,545	67.2
Black or African American	7,436,458	14.8	4,319,597	15.3	336,086	12.4	187,110	12.6	171,604	11.7	12,448	17.5	3,599	11.3	3,965	13.0
Asian	2,414,479	4.8	1,382,852	4.9	127,388	4.7	66,915	4.5	69,195	4.7	4,842	6.8	1,005	3.2	1,719	5.6
Multiple races	1,043,988	2.1	581,322	2.1	37,089	1.4	15,742	1.1	23,769	1.6	1,833	2.6	492	1.6	534	1.7
American Indian or Alaska Native	295,371	0.6	169,938	0.6	12,221	0.5	5,839	0.4	6,960	0.5	427	0.6	224	0.7	184	0.6
Native Hawaiian or Other Pacific Islander	126,320	0.3	68,888	0.2	4,578	0.2	2,285	0.2	2,541	0.2	199	0.3	53	0.2	59	0.2
Unknown	6,404,611	12.7	3,524,454	12.5	174,830	6.5	83,114	5.6	100,001	6.8	7,658	10.8	1,984	6.3	2,362	7.7
Missing ³	2,162,200	4.3	1,199,311	4.3	78,858	2.9	40,650	2.7	44,108	3.0	2,505	3.5	518	1.6	1,189	3.9
HISPANIC																
No	34,035,087	67.7	19,095,658	67.7	277,632	10.2	129,801	8.7	164,894	11.2	12,662	17.8	2,811	8.9	3,729	12.2
Yes	8,076,246	16.1	4,595,168	16.3	2,166,614	79.9	1,236,283	83.2	1,143,750	78.0	50,514	70.9	25,696	81.0	24,109	78.9
Unknown	4,092,239	8.1	2,242,010	7.9	127,265	4.7	58,397	3.9	77,097	5.3	3,937	5.5	1,747	5.5	1,532	5.0
Missing ³	4,082,045	8.1	2,275,367	8.1	138,698	5.1	62,053	4.2	81,434	5.6	4,119	5.8	1,469	4.6	1,187	3.9
PAYER STATUS LAST VISIT IN 2024																
Private	19,823,388	39.4	11,209,102	39.7	930,046	34.3	384,036	25.8	616,370	42.0	36,816	51.7	16,018	50.5	14,287	46.8
Public	15,103,892	30.0	8,531,431	30.2	1,081,610	39.9	746,734	50.2	452,791	30.9	12,014	16.9	8,406	26.5	7,012	22.9
Other	1,873,611	3.7	990,175	3.5	59,832	2.2	23,402	1.6	39,122	2.7	3,033	4.3	1,227	3.9	894	2.9
Missing ³	13,484,726	26.8	7,477,495	26.5	638,721	23.6	332,362	22.4	358,892	24.5	19,369	27.2	6,072	19.1	8,364	27.4

¹Total includes 75 partners in PCORnet.
²Some totals may not add up due to masking low cell sizes.
³Missing includes those values that are null, refuse to answer, and no information.
⁴Denominator for percentage is the count for all female patients with menopausal conditions.

Table 2. Care setting and geographic characteristics for patients with a diagnosis code for menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2024 – December 31, 2024.^{1, 2}

	Total Patients		Females		Females with Menopausal Conditions		Asymptomatic Menopause ⁴		Menopausal and Other Perimenopausal Disorders ⁴		Excess Premenopausal Bleeding ⁴		Post-procedure Ovarian Failure ⁴		Premature Menopause ⁴	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	1,486,534	54.8	1,467,175	54.1	71,232	2.6	31,723	1.2	30,557	1.1
CARE SETTING ENCOUNTER 2024																
Ambulatory Visit	44,226,420	88.0	25,016,993	88.7	2,666,450	98.4	1,466,757	98.7	1,443,205	98.4	69,355	97.4	31,089	98.0	30,006	98.2
Emergency Department Visit	10,236,874	20.4	5,559,837	19.7	371,230	13.7	206,861	13.9	195,195	13.3	12,118	17.0	5,341	16.8	4,042	13.2
Telehealth Visit	8,126,336	16.2	4,930,863	17.5	726,674	26.8	368,029	24.8	434,209	29.6	24,326	34.2	11,533	36.4	10,868	35.6
Inpatient Hospital Stay	3,643,929	7.2	2,067,249	7.3	179,288	6.6	105,200	7.1	92,536	6.3	4,405	6.2	2,323	7.3	2,055	6.7
Emergency to Inpatient Stay	1,446,791	2.9	803,654	2.8	31,065	1.1	20,168	1.4	12,287	0.8	526	0.7	252	0.8	197	0.6
Non-Acute Institutional Stay	1,283,267	2.6	659,423	2.3	83,956	3.1	52,660	3.5	38,960	2.7	1,426	2.0	799	2.5	708	2.3
Observation Stay	639,119	1.3	349,136	1.2	38,019	1.4	23,023	1.5	18,943	1.3	885	1.2	503	1.6	454	1.5
AREA DEPRIVATION INDEX (ADI) QUARTILE BASED ON 5-DIGIT ZIP ³																
ADI Quartile 1 (Higher Socioeconomic Status)	19,048,625	37.9	10,631,580	37.7	1,184,454	43.7	654,682	44.0	655,411	44.7	28,380	39.8	11,839	37.3	14,081	46.1
ADI Quartile 2	8,858,022	17.6	4,976,851	17.6	483,800	17.9	270,739	18.2	254,062	17.3	12,646	17.8	6,350	20.0	5,328	17.4
ADI Quartile 3	9,985,809	19.9	5,651,148	20.0	514,165	19.0	289,794	19.5	263,024	17.9	13,553	19.0	7,193	22.7	5,383	17.6
ADI Quartile 4 (Lower Socioeconomic Status)	8,267,354	16.4	4,721,152	16.7	359,744	13.3	199,934	13.4	183,908	12.5	11,639	16.3	3,899	12.3	4,038	13.2
Missing ⁵	4,125,807	8.2	2,227,472	7.9	168,046	6.2	71,385	4.8	110,770	7.5	5,014	7.0	2,442	7.7	1,727	5.7
RURAL-URBAN COMMUTING AREA CODES BASED ON 5-DIGIT ZIP ⁶																
Metropolitan Area	40,451,989	80.4	22,831,865	80.9	2,209,166	81.5	1,226,361	82.5	1,188,910	81.0	58,088	81.5	24,016	75.7	25,699	84.1
Micropolitan Area	3,617,808	7.2	2,007,063	7.1	212,025	7.8	120,419	8.1	107,502	7.3	4,947	6.9	3,320	10.5	1,989	6.5
Small Town	1,453,436	2.9	802,168	2.8	84,400	3.1	47,590	3.2	42,637	2.9	2,134	3.0	1,317	4.2	847	2.8
Rural	1,012,413	2.0	544,588	1.9	60,438	2.2	34,680	2.3	29,809	2.0	1,506	2.1	966	3.0	552	1.8
Missing ⁵	3,749,971	7.5	2,022,519	7.2	144,180	5.3	57,484	3.9	98,317	6.7	4,557	6.4	2,104	6.6	1,470	4.8
U.S. CENSUS REGION																
South	17,805,971	35.4	10,155,500	36.0	940,121	34.7	538,130	36.2	494,755	33.7	19,868	27.9	11,089	35.0	8,675	28.4
West	10,217,238	20.3	5,642,792	20.0	634,790	23.4	330,111	22.2	371,380	25.3	18,060	25.4	8,464	26.7	8,223	26.9
Northeast	9,467,762	18.8	5,338,864	18.9	501,039	18.5	278,545	18.7	260,765	17.8	14,651	20.6	3,600	11.3	5,567	18.2
Midwest	8,900,893	17.7	4,936,663	17.5	528,481	19.5	303,729	20.4	268,701	18.3	15,368	21.6	6,745	21.3	7,430	24.3
Other	753,720	1.5	445,209	1.6	20,250	0.7	13,858	0.9	6,392	0.4	415	0.6	147	0.5	136	0.4
Missing ⁵	3,140,033	6.2	1,689,175	6.0	85,528	3.2	22,161	1.5	65,182	4.4	2,870	4.0	1,678	5.3	526	1.7
TOTAL UNIQUE PATIENT RECORDS WITH 5-DIGIT ZIP	46,654,037	92.8	26,243,021	93.0	2,566,494	94.7	1,429,289	96.1	1,369,110	93.3	66,699	93.6	29,624	93.4	29,094	95.2

¹Total includes 75 partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Area Deprivation Index (ADI): Patient 5-digit zip codes are mapped to socioeconomic status by normalized Area Deprivation Index (ADI) value (0-100). Lower values are associated with higher socioeconomic status (SES) and higher values are associated with lower SES. A ranking of 1 indicates the highest level of SES within the nation and an ADI with a ranking of 100 indicates the lowest level of SES. In this table, values are grouped into quartiles using the count of zip codes. Quartile 1 (Higher SES) represents the lowest range of ADI values and Quartile 4 (Lower SES) represents the highest range of ADI values (Q1=0-38, Q2=39-43, Q3=44-49, and Q4=50-100). For additional information regarding the ADI index, see the Neighborhood Atlas: <https://www.neighborhoodatlas.medicine.wisc.edu>. Note that the Area Deprivation Index (ADI) is designed for validity at the 9-digit zip or census block group level rather than the 5-digit zip level.

⁴Denominator for percentage is the count for all female patients with menopausal conditions.

⁵Missing includes those values that are null, refuse to answer, and no information.

⁶Represented as combined [Rural-Urban Commuting Area \(RUCA\) codes](#) as referenced on https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4. RUCA contains 10 primary and 21 secondary codes which delineate components of rural and urban areas and define county-level metropolitan (urban) and nonmetropolitan areas (i.e., micropolitan/large rural areas, small towns, and isolated rural areas).

Table 3. Chronic conditions, procedures, and medication prescribing for patients with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2024 – December 31, 2024, and a recorded diagnosis code for a menopausal condition between January 1, 2020 – December 31, 2024.^{1, 2}

	Total Patients		Females		Females with Menopausal Conditions		Asymptomatic Menopause ⁴		Menopausal and Other Perimenopausal Disorders ⁴		Excess Premenopausal Bleeding ⁴		Post-procedure Ovarian Failure ⁴		Premature Menopause ⁴	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	1,486,534	54.8	1,467,175	54.1	71,232	2.6	31,723	1.2	30,557	1.1
CO-OCCURRING CHRONIC CONDITIONS (2020-2024)																
Hypertension	12,180,973	24.2	6,466,610	22.9	1,412,971	52.1	888,809	59.8	673,218	45.9	24,053	33.8	13,309	42.0	11,922	39.0
Hyperlipidemia	12,165,213	24.2	6,447,321	22.9	1,615,838	59.6	1,017,836	68.5	785,441	53.5	24,797	34.8	14,959	47.2	15,499	50.7
Diagnosis of obesity/overweight	10,336,723	20.6	6,194,178	22.0	1,059,553	39.1	595,057	40.0	565,221	38.5	32,671	45.9	15,178	47.8	12,287	40.2
Anxiety	7,719,755	15.4	5,234,873	18.6	856,413	31.6	452,920	30.5	492,764	33.6	27,154	38.1	14,188	44.7	11,229	36.7
Depression	5,749,787	11.4	3,947,106	14.0	699,897	25.8	382,570	25.7	389,539	26.6	20,439	28.7	11,366	35.8	8,886	29.1
Type 2 diabetes	5,639,150	11.2	2,969,022	10.5	614,191	22.7	377,266	25.4	299,227	20.4	12,020	16.9	5,857	18.5	5,582	18.3
Insomnia/sleep disorders (other than sleep apnea)	4,439,405	8.8	2,662,387	9.4	645,625	23.8	364,280	24.5	363,649	24.8	15,024	21.1	9,877	31.1	7,859	25.7
Sleep apnea/obstructive sleep apnea	3,836,975	7.6	1,750,776	6.2	402,238	14.8	232,705	15.7	219,430	15.0	8,891	12.5	5,364	16.9	4,499	14.7
Coronary artery disease	3,732,352	7.4	1,586,865	5.6	389,258	14.4	262,461	17.7	177,770	12.1	3,850	5.4	2,888	9.1	3,299	10.8
Hypoglycemia/hyperglycemia	3,444,446	6.8	1,810,191	6.4	405,922	15.0	254,689	17.1	196,481	13.4	7,796	10.9	4,434	14.0	4,101	13.4
Hypothyroidism	3,435,233	6.8	2,552,663	9.0	614,290	22.7	373,054	25.1	315,572	21.5	10,867	15.3	7,173	22.6	7,312	23.9
Chronic kidney disease	2,830,088	5.6	1,421,819	5.0	351,552	13.0	238,069	16.0	154,281	10.5	3,714	5.2	2,696	8.5	3,036	9.9
Atrial fibrillation (Afib)	2,122,356	4.2	966,397	3.4	214,231	7.9	139,162	9.4	101,527	6.9	2,696	3.8	1,476	4.7	1,687	5.5
Heart failure	1,968,972	3.9	951,949	3.4	193,207	7.1	127,020	8.5	88,086	6.0	2,429	3.4	1,382	4.4	1,665	5.4
Osteopenia	1,868,481	3.7	1,577,965	5.6	762,209	28.1	598,441	40.3	288,288	19.6	2,367	3.3	5,893	18.6	9,080	29.7
Peripheral artery disease	1,517,260	3.0	762,753	2.7	220,377	8.1	160,110	10.8	90,717	6.2	1,346	1.9	1,365	4.3	1,707	5.6
Non-alcoholic fatty liver disease	1,508,674	3.0	847,927	3.0	204,110	7.5	118,030	7.9	110,271	7.5	5,212	7.3	3,124	9.8	2,711	8.9
Malignant breast cancer	759,253	1.5	695,864	2.5	220,956	8.2	148,679	10.0	103,242	7.0	2,659	3.7	2,719	8.6	2,874	9.4
Hyperthyroidism	461,183	0.9	349,928	1.2	74,278	2.7	43,321	2.9	39,914	2.7	1,928	2.7	966	3.0	1,070	3.5
Type 1 diabetes	450,204	0.9	231,696	0.8	31,941	1.2	17,567	1.2	17,846	1.2	957	1.3	460	1.5	474	1.6
Polycystic/polymetabolic ovarian syndrome (PMOS/PCOS)	421,740	0.8	411,794	1.5	23,325	0.9	7,011	0.5	15,453	1.1	3,090	4.3	902	2.8	556	1.8
Atrial flutter (AFlutter)	414,645	0.8	162,463	0.6	38,984	1.4	25,956	1.7	18,168	1.2	433	0.6	259	0.8	298	1.0
Dyslipidemia (other than hyperlipidemia)	269,613	0.5	135,741	0.5	33,526	1.2	20,355	1.4	17,393	1.2	817	1.1	357	1.1	377	1.2
Gastroparesis	183,039	0.4	130,070	0.5	23,013	0.8	12,479	0.8	13,125	0.9	570	0.8	555	1.7	438	1.4
Metabolic syndrome	107,965	0.2	66,548	0.2	16,255	0.6	8,587	0.6	9,730	0.7	523	0.7	299	0.9	256	0.8
POTENTIAL MENOPAUSAL SYMPTOMS (2020-2024)																
Fatigue	5,957,186	11.8	3,753,233	13.3	799,445	29.5	457,383	30.8	435,672	29.7	22,578	31.7	11,359	35.8	10,331	33.8
Headaches/migraines	5,938,424	11.8	4,170,882	14.8	635,470	23.4	324,642	21.8	376,160	25.6	23,470	32.9	11,087	34.9	9,158	30.0
Palpitations	2,293,132	4.6	1,566,171	5.6	338,703	12.5	188,604	12.7	192,245	13.1	9,764	13.7	4,537	14.3	4,215	13.8
Symptoms consistent with mild cognitive dysfunction and awareness	1,874,027	3.7	1,025,945	3.6	192,259	7.1	117,236	7.9	98,620	6.7	3,547	5.0	2,501	7.9	2,257	7.4
Urinary tract infection	582,580	1.2	475,872	1.7	155,228	5.7	77,836	5.2	104,138	7.1	2,430	3.4	1,765	5.6	1,318	4.3
Reduced libido/sexual dysfunction	251,761	0.5	113,464	0.4	48,447	1.8	17,810	1.2	40,687	2.8	1,295	1.8	1,560	4.9	1,154	3.8
MEDICATIONS PRESCRIBED (2024 ONLY)																
Any antihypertensives	7,517,140	14.9	3,989,735	14.1	910,449	33.6	584,672	39.3	422,298	28.8	14,257	20.0	7,971	25.1	7,362	24.1
Diuretics	3,517,551	7.0	1,970,531	7.0	447,095	16.5	288,321	19.4	205,609	14.0	6,910	9.7	4,065	12.8	3,549	11.6
Calcium channel blockers	3,193,102	6.3	1,680,663	6.0	375,356	13.8	249,494	16.8	165,593	11.3	5,212	7.3	2,887	9.1	2,989	9.8
Angiotensin receptor blockers (ARBs)	2,620,231	5.2	1,378,591	4.9	367,216	13.5	241,754	16.3	167,399	11.4	5,005	7.0	2,932	9.2	2,743	9.0
Angiotensin-converting enzyme (ACE) inhibitors	2,200,497	4.4	1,007,834	3.6	249,173	9.2	161,595	10.9	112,034	7.6	3,740	5.3	2,104	6.6	1,831	6.0
Beta blockers	166,855	0.3	88,731	0.3	18,832	0.7	12,479	0.8	8,284	0.6	273	0.4	162	0.5	122	0.4
Selective serotonin reuptake inhibitors (SSRIs)	2,881,029	5.7	1,979,170	7.0	334,126	12.3	182,081	12.2	185,191	12.6	9,137	12.8	4,677	14.7	3,649	11.9
Hormonal therapies	2,184,875	4.3	2,143,796	7.6	501,800	18.5	158,649	10.7	425,885	29.0	17,973	25.2	12,370	39.0	7,966	26.1
GLP-1 receptor agonists	1,517,046	3.0	978,713	3.5	210,823	7.8	107,348	7.2	122,958	8.4	7,407	10.4	3,332	10.5	2,803	9.2
Sleep medications	997,381	2.0	594,097	2.1	126,453	4.7	72,779	4.9	68,649	4.7	2,527	3.5	1,870	5.9	1,461	4.8
Serotonin norepinephrine reuptake inhibitors (SNRIs)	620,040	1.2	432,049	1.5	96,567	3.6	54,545	3.7	53,030	3.6	1,933	2.7	1,591	5.0	1,186	3.9
Medications for urinary incontinence	508,249	1.0	313,988	1.1	97,455	3.6	51,936	3.5	59,811	4.1	1,062	1.5	980	3.1	772	2.5
Osteoporosis medications	476,663	0.9	422,484	1.5	171,083	6.3	128,681	8.7	67,434	4.6	259	0.4	1,217	3.8	2,176	7.1
Weight-loss medications	40,279	0.1	33,605	0.1	6,881	0.3	2,835	0.2	4,640	0.3	313	0.4	163	0.5	130	0.4
Medications for hot flashes	11,571	<0.1	11,465	<0.1	8,309	0.3	2,795	0.2	7,403	0.5	155	0.2	365	1.2	136	0.4

PROCEDURES (2020-2024)																
Bone mineral density tests	2,288,071	4.6	2,034,148	7.2	1,122,797	41.4	906,536	61.0	394,320	26.9	3,370	4.7	9,283	29.3	14,493	47.4
Any behavioral health interventions	1,615,104	3.2	1,001,883	3.6	118,458	4.4	56,777	3.8	73,708	5.0	4,871	6.8	2,518	7.9	2,052	6.7
Endometrial biopsy	299,420	0.6	299,206	1.1	144,230	5.3	37,030	2.5	124,457	8.5	17,410	24.4	1,622	5.1	1,253	4.1
Hysterectomy	223,187	0.4	221,824	0.8	81,607	3.0	24,409	1.6	63,140	4.3	7,217	10.1	5,140	16.2	909	3.0
Salpingo-oophorectomy/oophorectomy	98,362	0.2	98,168	0.3	19,943	0.7	7,599	0.5	13,203	0.9	1,293	1.8	1,975	6.2	504	1.6
BODY MASS INDEX																
Adult: Underweight (<18.5 kg/m2)	484,755	1.0	349,910	1.2	39,881	1.5	23,769	1.6	20,104	1.4	619	0.9	367	1.2	671	2.2
Adult: Normal weight (18.5 - <25 kg/m2)	7,125,838	14.2	4,549,393	16.1	699,193	25.8	386,504	26.0	396,505	27.0	13,853	19.4	6,992	22.0	9,183	30.1
Adult: Overweight (25 - <30 kg/m2)	8,341,235	16.6	4,326,866	15.3	712,640	26.3	400,555	26.9	385,425	26.3	15,530	21.8	7,913	24.9	8,049	26.3
Adult: Obese class 1 (30 - <35 kg/m2)	5,453,441	10.8	3,023,589	10.7	475,062	17.5	267,135	18.0	249,295	17.0	12,269	17.2	6,214	19.6	5,039	16.5
Adult: Obese class 2 (35 - <40 kg/m2)	2,688,222	5.3	1,676,593	5.9	244,746	9.0	134,115	9.0	128,795	8.8	7,766	10.9	3,647	11.5	2,688	8.8
Adult: Obese class 3 (≥40 kg/m2)	2,113,498	4.2	1,474,216	5.2	183,552	6.8	92,312	6.2	101,382	6.9	8,309	11.7	2,995	9.4	1,975	6.5
Adult: Biologically implausible	867,726	1.7	519,581	1.8	49,817	1.8	25,418	1.7	26,093	1.8	1,135	1.6	436	1.4	354	1.2
Missing ³	16,083,053	32.0	8,766,509	31.1	302,134	11.1	156,510	10.5	158,770	10.8	9,875	13.9	2,894	9.1	2,514	8.2

¹Total includes 75 partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Missing includes those values that are null, refuse to answer, and no information.

⁴Denominator for percentage is the count for all female patients with menopausal conditions.

Table 4. Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2024 – December 31, 2024, for anti-hypertensives, hormonal therapies, selective serotonin reuptake inhibitors (SSRIs), GLP-1 medications, and osteoporosis medications prescribed in 2024.^{1,2}

	Total Patients		Females		Females with Menopausal Conditions		Antihypertensives ³		Hormonal Therapies ³		SSRIs ³		GLP-1 Receptor Agonists ³		Osteoporosis Medications ³	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	910,449	33.6	501,800	18.5	334,126	12.3	210,823	7.8	171,083	6.3
MENOPAUSAL CONDITIONS																
Asymptomatic menopausal state	1,496,947	3.0	1,486,534	5.3	1,486,534	54.8	584,672	64.2	158,649	31.6	182,081	54.5	107,348	50.9	128,681	75.2
Menopausal and other perimenopausal disorders ⁴	1,482,193	2.9	1,467,175	5.2	1,467,175	54.1	422,298	46.4	425,885	84.9	185,191	55.4	122,958	58.3	67,434	39.4
Menopausal climacteric states	677,966	1.3	671,009	2.4	671,009	24.8	160,018	17.6	205,043	40.9	95,759	28.7	62,766	29.8	17,313	10.1
Postmenopausal atrophic vaginitis	536,667	1.1	531,906	1.9	531,906	19.6	161,246	17.7	213,328	42.5	62,014	18.6	36,004	17.1	37,977	22.2
Postmenopausal bleeding	282,105	0.6	279,334	1.0	279,334	10.3	92,230	10.1	51,983	10.4	29,445	8.8	27,212	12.9	9,805	5.7
Other menopausal and peri-menopausal disorders	116,999	0.2	116,442	0.4	116,442	4.3	40,251	4.4	44,910	8.9	15,194	4.5	9,477	4.5	8,674	5.1
Unspecified menopausal and peri-menopausal disorders	96,390	0.2	95,751	0.3	95,751	3.5	31,020	3.4	18,651	3.7	12,363	3.7	7,204	3.4	5,808	3.4
Excessive bleeding in premenopause	71,946	0.1	71,232	0.3	71,232	2.6	14,257	1.6	17,973	3.6	9,137	2.7	7,407	3.5	259	0.2
Post-procedural ovarian failure	31,926	0.1	31,723	0.1	31,723	1.2	7,971	0.9	12,370	2.5	4,677	1.4	3,332	1.6	1,217	0.7
Premature menopause	30,931	0.1	30,557	0.1	30,557	1.1	7,362	0.8	7,966	1.6	3,649	1.1	2,803	1.3	2,176	1.3
AGE CATEGORIES																
Adults 35-54	11,548,474	23.0	6,898,408	24.5	572,791	21.1	105,456	11.6	164,009	32.7	77,117	23.1	57,722	27.4	5,423	3.2
Adults 55-64	6,319,268	12.6	3,525,577	12.5	662,016	24.4	173,128	19.0	153,324	30.6	75,583	22.6	63,882	30.3	23,363	13.7
Adults 65-74	6,236,732	12.4	3,435,779	12.2	885,785	32.7	350,503	38.5	108,547	21.6	105,359	31.5	66,669	31.6	74,922	43.8
Adults 75+	5,008,399	10.0	2,858,223	10.1	559,989	20.7	279,290	30.7	66,213	13.2	72,004	21.5	21,362	10.1	67,243	39.3
CO-OCCURRING CHRONIC CONDITIONS (2020-2024)																
Hypertension	12,180,973	24.2	6,466,610	22.9	1,412,971	52.1	848,464	93.2	202,220	40.3	202,068	60.5	152,884	72.5	106,165	62.1
Hyperlipidemia	12,165,213	24.2	6,447,321	22.9	1,615,838	59.6	724,996	79.6	248,797	49.6	233,709	69.9	164,690	78.1	127,118	74.3
Diagnosis of obesity/overweight	10,336,723	20.6	6,194,178	22.0	1,059,553	39.1	485,772	53.4	167,070	33.3	162,184	48.5	176,378	83.7	54,937	32.1
Anxiety	7,719,755	15.4	5,234,873	18.6	856,413	31.6	341,253	37.5	175,170	34.9	236,701	70.8	91,388	43.3	60,107	35.1
Depression	5,749,787	11.4	3,947,106	14.0	699,897	25.8	293,739	32.3	135,612	27.0	218,685	65.4	85,065	40.3	51,475	30.1
Type 2 diabetes	5,639,150	11.2	2,969,022	10.5	614,191	22.7	334,890	36.8	86,153	17.2	88,421	26.5	129,224	61.3	39,407	23.0
Insomnia/sleep disorders (other than sleep apnea)	4,439,405	8.8	2,662,387	9.4	645,625	23.8	275,407	30.2	132,127	26.3	130,834	39.2	73,806	35.0	52,064	30.4
Sleep apnea/obstructive sleep apnea	3,836,975	7.6	1,750,776	6.2	402,238	14.8	197,919	21.7	70,830	14.1	74,308	22.2	69,085	32.8	26,739	15.6
Coronary artery disease	3,732,352	7.4	1,586,865	5.6	389,258	14.4	214,072	23.5	54,370	10.8	60,360	18.1	41,760	19.8	36,176	21.1
Hypoglycemia/hyperglycemia	3,444,446	6.8	1,810,191	6.4	405,922	15.0	219,558	24.1	58,236	11.6	64,690	19.4	78,207	37.1	30,446	17.8
Hypothyroidism	3,435,233	6.8	2,552,663	9.0	614,290	22.7	245,389	27.0	109,526	21.8	92,070	27.6	58,943	28.0	49,367	28.9
Chronic kidney disease	2,830,088	5.6	1,421,819	5.0	351,552	13.0	211,987	23.3	46,622	9.3	56,105	16.8	40,281	19.1	32,596	19.1
Atrial fibrillation (Afib)	2,122,356	4.2	966,397	3.4	214,231	7.9	117,470	12.9	32,759	6.5	32,701	9.8	18,969	9.0	20,979	12.3
Heart failure	1,968,972	3.9	951,949	3.4	193,207	7.1	127,060	14.0	25,411	5.1	33,384	10.0	22,096	10.5	18,161	10.6
Osteopenia	1,868,481	3.7	1,577,965	5.6	762,209	28.1	297,726	32.7	99,699	19.9	95,348	28.5	45,342	21.5	92,813	54.3
Peripheral artery disease	1,517,260	3.0	762,753	2.7	220,377	8.1	128,098	14.1	26,129	5.2	34,686	10.4	19,500	9.2	23,782	13.9
Non-alcoholic fatty liver disease	1,508,674	3.0	847,927	3.0	204,110	7.5	94,594	10.4	32,698	6.5	31,227	9.3	36,440	17.3	12,415	7.3
Malignant breast cancer	759,253	1.5	695,864	2.5	220,956	8.2	76,082	8.4	20,744	4.1	26,467	7.9	15,917	7.5	27,002	15.8
Hyperthyroidism	461,183	0.9	349,928	1.2	74,278	2.7	31,113	3.4	13,144	2.6	10,224	3.1	7,548	3.6	6,381	3.7
Type 1 diabetes	450,204	0.9	231,696	0.8	31,941	1.2	16,123	1.8	6,244	1.2	5,125	1.5	5,462	2.6	2,804	1.6
Polycystic/polymetabolic ovarian syndrome (PMOS/PCOS)	421,740	0.8	411,794	1.5	23,325	0.9	7,781	0.9	6,991	1.4	3,863	1.2	5,086	2.4	776	0.5
Atrial flutter (AFlutter)	414,645	0.8	162,463	0.6	38,984	1.4	24,040	2.6	5,658	1.1	6,258	1.9	3,594	1.7	4,019	2.3
Dyslipidemia (other than hyperlipidemia)	269,613	0.5	135,741	0.5	33,526	1.2	14,937	1.6	6,288	1.3	5,096	1.5	3,999	1.9	2,758	1.6
Gastroparesis	183,039	0.4	130,070	0.5	23,013	0.8	11,616	1.3	4,700	0.9	4,382	1.3	3,623	1.7	1,824	1.1
Metabolic syndrome	107,965	0.2	66,548	0.2	16,255	0.6	8,101	0.9	3,316	0.7	2,718	0.8	5,475	2.6	762	0.4
POTENTIAL MENOPAUSAL SYMPTOMS (2020-2024)																
Fatigue	5,957,186	11.8	3,753,233	13.3	799,445	29.5	330,437	36.3	149,548	29.8	137,854	41.3	81,017	38.4	63,135	36.9
Headaches/migraines	5,938,424	11.8	4,170,882	14.8	635,470	23.4	248,441	27.3	134,370	26.8	107,369	32.1	67,736	32.1	43,416	25.4
Palpitations	2,293,132	4.6	1,566,171	5.6	338,703	12.5	147,713	16.2	67,507	13.5	50,673	15.2	33,721	16.0	24,868	14.5
Symptoms consistent with mild cognitive dysfunction and awareness	1,874,027	3.7	1,025,945	3.6	192,259	7.1	90,950	10.0	34,687	6.9	43,053	12.9	17,223	8.2	18,897	11.0
Urinary tract infection	582,580	1.2	475,872	1.7	155,228	5.7	73,905	8.1	47,449	9.5	26,568	8.0	16,284	7.7	14,460	8.5
Reduced libido/sexual dysfunction	251,761	0.5	113,464	0.4	48,447	1.8	10,138	1.1	20,962	4.2	6,999	2.1	5,205	2.5	1,656	1.0

MEDICATIONS PRESCRIBED (2024 ONLY)																
Any antihypertensives	7,517,140	14.9	3,989,735	14.1	910,449	33.6	910,449	100	138,677	27.6	162,517	48.6	123,052	58.4	78,947	46.1
Diuretics	3,517,551	7.0	1,970,531	7.0	447,095	16.5	447,095	49.1	66,255	13.2	81,849	24.5	66,467	31.5	35,159	20.6
Calcium channel blockers	3,193,102	6.3	1,680,663	6.0	375,356	13.8	375,356	41.2	52,330	10.4	66,955	20.0	43,586	20.7	35,748	20.9
Angiotensin receptor blockers (ARBs)	2,620,231	5.2	1,378,591	4.9	367,216	13.5	367,216	40.3	54,826	10.9	65,371	19.6	55,281	26.2	31,069	18.2
Angiotensin-converting enzyme (ACE) inhibitors	2,200,497	4.4	1,007,834	3.6	249,173	9.2	249,173	27.4	35,024	7.0	45,385	13.6	38,335	18.2	21,706	12.7
Beta blockers	166,855	0.3	88,731	0.3	18,832	0.7	18,832	2.1	3,063	0.6	3,751	1.1	2,598	1.2	1,674	1.0
Selective serotonin reuptake inhibitors (SSRIs)	2,881,029	5.7	1,979,170	7.0	334,126	12.3	162,517	17.9	72,002	14.3	334,126	100	42,722	20.3	27,475	16.1
Hormonal therapies	2,184,875	4.3	2,143,796	7.6	501,800	18.5	138,677	15.2	501,800	100	72,002	21.5	44,355	21.0	24,126	14.1
GLP-1 receptor agonists	1,517,046	3.0	978,713	3.5	210,823	7.8	123,052	13.5	44,355	8.8	42,722	12.8	210,823	100	8,751	5.1
Sleep medications	997,381	2.0	594,097	2.1	126,453	4.7	66,538	7.3	28,115	5.6	41,476	12.4	16,677	7.9	12,296	7.2
Serotonin norepinephrine reuptake inhibitors (SNRIs)	620,040	1.2	432,049	1.5	96,567	3.6	54,808	6.0	20,335	4.1	11,172	3.3	17,071	8.1	8,928	5.2
Medications for urinary incontinence	508,249	1.0	313,988	1.1	97,455	3.6	52,057	5.7	29,841	5.9	21,214	6.3	12,225	5.8	10,022	5.9
Osteoporosis medications	476,663	0.9	422,484	1.5	171,083	6.3	78,947	8.7	24,126	4.8	27,475	8.2	8,751	4.2	171,083	100
Weight-loss medications	40,279	0.1	33,605	0.1	6,881	0.3	2,746	0.3	1,989	0.4	1,356	0.4	2,730	1.3	203	0.1
Medications for hot flashes	11,571	<0.1	11,465	<0.1	8,309	0.3	2,436	0.3	2,754	0.5	1,766	0.5	1,345	0.6	398	0.2

¹Total includes 75 partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Denominator for percentage is the count for all female patients with menopausal conditions.

⁴Menopausal and other perimenopausal disorders include the following conditions based on ICD-10 codes: menopausal climacteric states (N95.1), postmenopausal atrophic vaginitis (N95.2), postmenopausal bleeding (N95.0), other menopausal and peri-menopausal disorders (N95.8), and unspecified menopausal and peri-menopausal disorders (N95.9).

Table 5. Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2024 – December 31, 2024, for sleep medications, medications for urinary incontinence, serotonin and norepinephrine reuptake inhibitors (SNRIs), medications for hot flashes, and weight-loss medications prescribed in 2024.^{1,2}

	Total Patients		Females		Females with Menopausal Conditions		Sleep Medications ³		Medications for Urinary Incontinence ³		SNRIs ³		Medications for Hot Flashes ³		Weight-Loss Medications ³	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	126,453	4.7	97,455	3.6	96,567	3.6	8,309	0.3	6,881	0.3
MENOPAUSAL CONDITIONS⁴																
Asymptomatic menopausal state	1,496,947	3.0	1,486,534	5.3	1,486,534	54.8	72,779	57.6	51,936	53.3	54,545	56.5	2,795	33.6	2,835	41.2
Menopausal and other perimenopausal disorders ⁴	1,482,193	2.9	1,467,175	5.2	1,467,175	54.1	68,649	54.3	59,811	61.4	53,030	54.9	7,403	89.1	4,640	67.4
Menopausal climacteric states	677,966	1.3	671,009	2.4	671,009	24.8	32,134	25.4	15,629	16.0	23,731	24.6	6,711	80.8	2,909	42.3
Postmenopausal atrophic vaginitis	536,667	1.1	531,906	1.9	531,906	19.6	26,183	20.7	34,662	35.6	20,005	20.7	1,266	15.2	1,121	16.3
Postmenopausal bleeding	282,105	0.6	279,334	1.0	279,334	10.3	11,356	9.0	9,264	9.5	10,076	10.4	794	9.6	782	11.4
Other menopausal and peri-menopausal disorders	116,999	0.2	116,442	0.4	116,442	4.3	6,059	4.8	8,329	8.5	4,948	5.1	480	5.8	337	4.9
Unspecified menopausal and peri-menopausal disorders	96,390	0.2	95,751	0.3	95,751	3.5	4,833	3.8	2,903	3.0	3,480	3.6	450	5.4	272	4.0
Excessive bleeding in premenopause	71,946	0.1	71,232	0.3	71,232	2.6	2,527	2.0	1,062	1.1	1,933	2.0	155	1.9	313	4.5
Post-procedural ovarian failure	31,926	0.1	31,723	0.1	31,723	1.2	1,870	1.5	980	1.0	1,591	1.6	365	4.4	163	2.4
Premature menopause	30,931	0.1	30,557	0.1	30,557	1.1	1,461	1.2	772	0.8	1,186	1.2	136	1.6	130	1.9
AGE CATEGORIES																
Adults 35-54	11,548,474	23.0	6,898,408	24.5	572,791	21.1	23,999	19.0	10,913	11.2	18,563	19.2	3,846	46.3	2,830	41.1
Adults 55-64	6,319,268	12.6	3,525,577	12.5	662,016	24.4	28,833	22.8	18,119	18.6	23,281	24.1	3,050	36.7	2,227	32.4
Adults 65-74	6,236,732	12.4	3,435,779	12.2	885,785	32.7	43,663	34.5	33,893	34.8	32,692	33.9	1,085	13.1	1,482	21.5
Adults 75+	5,008,399	10.0	2,858,223	10.1	559,989	20.7	29,112	23.0	34,226	35.1	21,415	22.2	284	3.4	267	3.9
CO-OCCURRING CHRONIC CONDITIONS (2020-2024)																
Hypertension	12,180,973	24.2	6,466,610	22.9	1,412,971	52.1	82,149	65.0	66,868	68.6	67,817	70.2	3,558	42.8	3,646	53.0
Hyperlipidemia	12,165,213	24.2	6,447,321	22.9	1,615,838	59.6	91,095	72.0	69,907	71.7	71,028	73.6	4,160	50.1	4,338	63.0
Diagnosis of obesity/overweight	10,336,723	20.6	6,194,178	22.0	1,059,553	39.1	62,491	49.4	51,074	52.4	56,189	58.2	3,658	44.0	6,389	92.8
Anxiety	7,719,755	15.4	5,234,873	18.6	856,413	31.6	77,507	61.3	41,917	43.0	59,782	61.9	3,441	41.4	3,145	45.7
Depression	5,749,787	11.4	3,947,106	14.0	699,897	25.8	71,353	56.4	40,647	41.7	62,071	64.3	2,656	32.0	2,653	38.6
Type 2 diabetes	5,639,150	11.2	2,969,022	10.5	614,191	22.7	37,513	29.7	32,106	32.9	34,552	35.8	1,391	16.7	1,104	16.0
Insomnia/sleep disorders (other than sleep apnea)	4,439,405	8.8	2,662,387	9.4	645,625	23.8	100,378	79.4	35,193	36.1	46,652	48.3	2,760	33.2	2,423	35.2
Sleep apnea/obstructive sleep apnea	3,836,975	7.6	1,750,776	6.2	402,238	14.8	31,804	25.2	26,018	26.7	30,469	31.6	1,349	16.2	1,946	28.3
Coronary artery disease	3,732,352	7.4	1,586,865	5.6	389,258	14.4	28,035	22.2	22,477	23.1	23,103	23.9	785	9.4	693	10.1
Hypoglycemia/hyperglycemia	3,444,446	6.8	1,810,191	6.4	405,922	15.0	28,650	22.7	21,486	22.0	25,056	25.9	928	11.2	910	13.2
Hypothyroidism	3,435,233	6.8	2,552,663	9.0	614,290	22.7	37,727	29.8	28,535	29.3	29,971	31.0	1,682	20.2	1,809	26.3
Chronic kidney disease	2,830,088	5.6	1,421,819	5.0	351,552	13.0	26,432	20.9	21,755	22.3	21,364	22.1	609	7.3	649	9.4
Atrial fibrillation (Afib)	2,122,356	4.2	966,397	3.4	214,231	7.9	14,988	11.9	12,049	12.4	11,486	11.9	373	4.5	397	5.8
Heart failure	1,968,972	3.9	951,949	3.4	193,207	7.1	16,793	13.3	12,748	13.1	14,015	14.5	331	4.0	293	4.3
Osteopenia	1,868,481	3.7	1,577,965	5.6	762,209	28.1	39,584	31.3	32,066	32.9	30,615	31.7	1,388	16.7	1,203	17.5
Peripheral artery disease	1,517,260	3.0	762,753	2.7	220,377	8.1	16,871	13.3	14,824	15.2	14,636	15.2	291	3.5	313	4.5
Non-alcoholic fatty liver disease	1,508,674	3.0	847,927	3.0	204,110	7.5	13,346	10.6	10,413	10.7	12,437	12.9	633	7.6	863	12.5
Malignant breast cancer	759,253	1.5	695,864	2.5	220,956	8.2	11,483	9.1	8,989	9.2	9,026	9.3	1,678	20.2	463	6.7
Hyperthyroidism	461,183	0.9	349,928	1.2	74,278	2.7	4,459	3.5	3,082	3.2	3,607	3.7	254	3.1	217	3.2
Type 1 diabetes	450,204	0.9	231,696	0.8	31,941	1.2	2,276	1.8	1,613	1.7	2,164	2.2	94	1.1	80	1.2
Polycystic/polymetabolic ovarian syndrome (PMOS/PCOS)	421,740	0.8	411,794	1.5	23,325	0.9	1,359	1.1	768	0.8	1,206	1.2	112	1.3	199	2.9
Atrial flutter (AFlutter)	414,645	0.8	162,463	0.6	38,984	1.4	3,124	2.5	2,395	2.5	2,345	2.4	53	0.6	67	1.0
Dyslipidemia (other than hyperlipidemia)	269,613	0.5	135,741	0.5	33,526	1.2	1,991	1.6	1,461	1.5	1,500	1.6	88	1.1	133	1.9
Gastroparesis	183,039	0.4	130,070	0.5	23,013	0.8	2,718	2.1	1,831	1.9	2,636	2.7	99	1.2	70	1.0
Metabolic syndrome	107,965	0.2	66,548	0.2	16,255	0.6	1,158	0.9	813	0.8	1,020	1.1	85	1.0	233	3.4
POTENTIAL MENOPAUSAL SYMPTOMS (2020-2024)																
Fatigue	5,957,186	11.8	3,753,233	13.3	799,445	29.5	58,621	46.4	40,822	41.9	49,931	51.7	2,683	32.3	2,684	39.0
Headaches/migraines	5,938,424	11.8	4,170,882	14.8	635,470	23.4	46,582	36.8	29,866	30.6	41,110	42.6	2,624	31.6	2,348	34.1
Palpitations	2,293,132	4.6	1,566,171	5.6	338,703	12.5	21,073	16.7	13,837	14.2	17,278	17.9	1,148	13.8	997	14.5
Symptoms consistent with mild cognitive dysfunction and awareness	1,874,027	3.7	1,025,945	3.6	192,259	7.1	20,807	16.5	14,002	14.4	16,349	16.9	589	7.1	436	6.3
Urinary tract infection	582,580	1.2	475,872	1.7	155,228	5.7	12,961	10.2	18,724	19.2	10,996	11.4	342	4.1	338	4.9
Reduced libido/sexual dysfunction	251,761	0.5	113,464	0.4	48,447	1.8	2,853	2.3	1,486	1.5	1,951	2.0	365	4.4	275	4.0

MEDICATIONS PRESCRIBED (2024 ONLY)																
Any antihypertensives	7,517,140	14.9	3,989,735	14.1	910,449	33.6	66,538	52.6	52,057	53.4	54,808	56.8	2,436	29.3	2,746	39.9
Diuretics	3,517,551	7.0	1,970,531	7.0	447,095	16.5	35,926	28.4	26,542	27.2	29,366	30.4	1,224	14.7	1,572	22.8
Calcium channel blockers	3,193,102	6.3	1,680,663	6.0	375,356	13.8	29,340	23.2	23,034	23.6	23,630	24.5	861	10.4	846	12.3
Angiotensin receptor blockers (ARBs)	2,620,231	5.2	1,378,591	4.9	367,216	13.5	26,077	20.6	21,220	21.8	22,525	23.3	969	11.7	1,156	16.8
Angiotensin-converting enzyme (ACE) inhibitors	2,200,497	4.4	1,007,834	3.6	249,173	9.2	17,557	13.9	14,085	14.5	14,430	14.9	574	6.9	655	9.5
Beta blockers	166,855	0.3	88,731	0.3	18,832	0.7	1,667	1.3	1,102	1.1	1,309	1.4	66	0.8	50	0.7
Selective serotonin reuptake inhibitors (SSRIs)	2,881,029	5.7	1,979,170	7.0	334,126	12.3	41,476	32.8	21,214	21.8	11,172	11.6	1,766	21.3	1,356	19.7
Hormonal therapies	2,184,875	4.3	2,143,796	7.6	501,800	18.5	28,115	22.2	29,841	30.6	20,335	21.1	2,754	33.1	1,989	28.9
GLP-1 receptor agonists	1,517,046	3.0	978,713	3.5	210,823	7.8	16,677	13.2	12,225	12.5	17,071	17.7	1,345	16.2	2,730	39.7
Sleep medications	997,381	2.0	594,097	2.1	126,453	4.7	126,453	100	10,191	10.5	15,725	16.3	641	7.7	539	7.8
Serotonin norepinephrine reuptake inhibitors (SNRIs)	620,040	1.2	432,049	1.5	96,567	3.6	15,725	12.4	9,018	9.3	96,567	100	532	6.4	435	6.3
Medications for urinary incontinence	508,249	1.0	313,988	1.1	97,455	3.6	10,191	8.1	97,455	100	9,018	9.3	462	5.6	347	5.0
Osteoporosis medications	476,663	0.9	422,484	1.5	171,083	6.3	12,296	9.7	10,022	10.3	8,928	9.2	398	4.8	203	3.0
Weight-loss medications	40,279	0.1	33,605	0.1	6,881	0.3	539	0.4	347	0.4	435	0.5	68	0.8	6,881	100
Medications for hot flashes	11,571	<0.1	11,465	<0.1	8,309	0.3	641	0.5	462	0.5	532	0.6	8,309	100	68	1.0

¹Total includes 75 partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Denominator for percentage is the count for all female patients with menopausal conditions.

⁴Menopausal and other perimenopausal disorders include the following conditions based on ICD-10 codes: menopausal climacteric states (N95.1), postmenopausal atrophic vaginitis (N95.2), postmenopausal bleeding (N95.0), other menopausal and peri-menopausal disorders (N95.8), and unspecified menopausal and peri-menopausal disorders (N95.9).

Table 6. Characteristics of patients with menopausal conditions with a face-to-face clinical encounter at a site participating in PCORnet® between January 1, 2024 – December 31, 2024, for selected diagnostic testing, surgeries, and behavioral health interventions delivered in 2024.^{1, 2}

	Total Patients		Females		Females with Menopausal Conditions		Bone Mineral Density Test ³		Any Behavioral Health Interventions ³		Endometrial Biopsy ³		Hysterectomy ³		Salpingo-oophorectomy ³	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	50,285,617	100	28,208,203	56.1	2,710,209	9.6	453,647	16.7	50,079	1.8	39,116	1.4	20,695	0.8	4,589	0.2
MENOPAUSAL CONDITIONS																
Asymptomatic menopausal state	1,496,947	3.0	1,486,534	5.3	1,486,534	54.8	372,532	82.1	23,682	47.3	8,718	22.3	5,260	25.4	1,673	36.5
Menopausal and other perimenopausal disorders ⁴	1,482,193	2.9	1,467,175	5.2	1,467,175	54.1	152,604	33.6	31,429	62.8	34,071	87.1	16,066	77.6	3,021	65.8
Menopausal climacteric states	677,966	1.3	671,009	2.4	671,009	24.8	49,781	11.0	16,427	32.8	11,731	30.0	4,664	22.5	1,436	31.3
Postmenopausal atrophic vaginitis	536,667	1.1	531,906	1.9	531,906	19.6	70,081	15.4	10,748	21.5	4,795	12.3	4,138	20.0	968	21.1
Postmenopausal bleeding	282,105	0.6	279,334	1.0	279,334	10.3	25,622	5.6	5,371	10.7	26,065	66.6	9,141	44.2	667	14.5
Other menopausal and peri-menopausal disorders	116,999	0.2	116,442	0.4	116,442	4.3	20,769	4.6	2,812	5.6	1,285	3.3	856	4.1	293	6.4
Unspecified menopausal and peri-menopausal disorders	96,390	0.2	95,751	0.3	95,751	3.5	16,268	3.6	2,041	4.1	969	2.5	497	2.4	183	4.0
Excessive bleeding in premenopause	71,946	0.1	71,232	0.3	71,232	2.6	1,297	0.3	1,976	3.9	4,692	12.0	2,163	10.5	296	6.5
Post-procedural ovarian failure	31,926	0.1	31,723	0.1	31,723	1.2	3,522	0.8	1,114	2.2	252	0.6	1,027	5.0	383	8.3
Premature menopause	30,931	0.1	30,557	0.1	30,557	1.1	5,889	1.3	852	1.7	344	0.9	194	0.9	86	1.9
AGE CATEGORIES																
Adults 35-54	11,548,474	23.0	6,898,408	24.5	572,791	21.1	27,035	6.0	15,498	30.9	16,204	41.4	7,544	36.5	2,067	45.0
Adults 55-64	6,319,268	12.6	3,525,577	12.5	662,016	24.4	81,845	18.0	12,963	25.9	12,867	32.9	5,409	26.1	1,040	22.7
Adults 65-74	6,236,732	12.4	3,435,779	12.2	885,785	32.7	223,917	49.4	14,176	28.3	6,726	17.2	5,157	24.9	904	19.7
Adults 75+	5,008,399	10.0	2,858,223	10.1	559,989	20.7	120,092	26.5	6,430	12.8	3,080	7.9	2,255	10.9	383	8.3
CO-OCCURRING CHRONIC CONDITIONS (2020-2024)																
Hypertension	12,180,973	24.2	6,466,610	22.9	1,412,971	52.1	259,844	57.3	27,816	55.5	17,913	45.8	10,815	52.3	2,055	44.8
Hyperlipidemia	12,165,213	24.2	6,447,321	22.9	1,615,838	59.6	308,356	68.0	32,029	64.0	18,030	46.1	9,930	48.0	2,105	45.9
Diagnosis of obesity/overweight	10,336,723	20.6	6,194,178	22.0	1,059,553	39.1	165,107	36.4	26,061	52.0	17,734	45.3	10,025	48.4	1,921	41.9
Anxiety	7,719,755	15.4	5,234,873	18.6	856,413	31.6	132,608	29.2	39,663	79.2	11,687	29.9	6,478	31.3	1,785	38.9
Depression	5,749,787	11.4	3,947,106	14.0	699,897	25.8	110,528	24.4	37,110	74.1	9,144	23.4	4,995	24.1	1,325	28.9
Type 2 diabetes	5,639,150	11.2	2,969,022	10.5	614,191	22.7	107,154	23.6	12,688	25.3	8,842	22.6	4,982	24.1	934	20.4
Insomnia/sleep disorders (other than sleep apnea)	4,439,405	8.8	2,662,387	9.4	645,625	23.8	109,031	24.0	25,784	51.5	7,789	19.9	3,693	17.8	1,120	24.4
Sleep apnea/obstructive sleep apnea	3,836,975	7.6	1,750,776	6.2	402,238	14.8	71,817	15.8	14,222	28.4	6,505	16.6	3,350	16.2	723	15.8
Coronary artery disease	3,732,352	7.4	1,586,865	5.6	389,258	14.4	78,321	17.3	7,986	15.9	4,158	10.6	2,350	11.4	522	11.4
Hypoglycemia/hyperglycemia	3,444,446	6.8	1,810,191	6.4	405,922	15.0	73,431	16.2	9,839	19.6	5,004	12.8	2,616	12.6	556	12.1
Hypothyroidism	3,435,233	6.8	2,552,663	9.0	614,290	22.7	114,608	25.3	12,610	25.2	7,299	18.7	4,223	20.4	952	20.7
Chronic kidney disease	2,830,088	5.6	1,421,819	5.0	351,552	13.0	67,727	14.9	6,948	13.9	3,655	9.3	2,089	10.1	451	9.8
Atrial fibrillation (Afib)	2,122,356	4.2	966,397	3.4	214,231	7.9	40,085	8.8	3,228	6.4	2,538	6.5	1,521	7.3	301	6.6
Heart failure	1,968,972	3.9	951,949	3.4	193,207	7.1	34,152	7.5	4,151	8.3	2,381	6.1	1,181	5.7	255	5.6
Osteopenia	1,868,481	3.7	1,577,965	5.6	762,209	28.1	244,097	53.8	13,259	26.5	4,757	12.2	2,606	12.6	820	17.9
Peripheral artery disease	1,517,260	3.0	762,753	2.7	220,377	8.1	47,523	10.5	4,857	9.7	1,796	4.6	1,085	5.2	220	4.8
Non-alcoholic fatty liver disease	1,508,674	3.0	847,927	3.0	204,110	7.5	36,316	8.0	5,733	11.4	3,243	8.3	1,719	8.3	466	10.2
Malignant breast cancer	759,253	1.5	695,864	2.5	220,956	8.2	55,809	12.3	4,181	8.3	2,748	7.0	1,578	7.6	778	17.0
Hyperthyroidism	461,183	0.9	349,928	1.2	74,278	2.7	13,942	3.1	1,589	3.2	953	2.4	543	2.6	141	3.1
Type 1 diabetes	450,204	0.9	231,696	0.8	31,941	1.2	5,415	1.2	670	1.3	435	1.1	226	1.1	65	1.4
Polycystic/polymetabolic ovarian syndrome (PMOS/PCOS)	421,740	0.8	411,794	1.5	23,325	0.9	2,121	0.5	788	1.6	672	1.7	428	2.1	129	2.8
Atrial flutter (AFlutter)	414,645	0.8	162,463	0.6	38,984	1.4	7,415	1.6	724	1.4	458	1.2	273	1.3	57	1.2
Dyslipidemia (other than hyperlipidemia)	269,613	0.5	135,741	0.5	33,526	1.2	5,967	1.3	653	1.3	414	1.1	176	0.9	49	1.1
Gastroparesis	183,039	0.4	130,070	0.5	23,013	0.8	3,861	0.9	1,123	2.2	274	0.7	137	0.7	49	1.1
Metabolic syndrome	107,965	0.2	66,548	0.2	16,255	0.6	2,560	0.6	556	1.1	308	0.8	144	0.7	28	0.6
POTENTIAL MENOPAUSAL SYMPTOMS (2020-2024)																
Fatigue	5,957,186	11.8	3,753,233	13.3	799,445	29.5	134,545	29.7	23,895	47.7	10,644	27.2	5,249	25.4	1,349	29.4
Headaches/migraines	5,938,424	11.8	4,170,882	14.8	635,470	23.4	98,681	21.8	20,799	41.5	9,574	24.5	4,606	22.3	1,314	28.6
Palpitations	2,293,132	4.6	1,566,171	5.6	338,703	12.5	58,710	12.9	9,006	18.0	4,808	12.3	2,165	10.5	591	12.9
Symptoms consistent with mild cognitive dysfunction and awareness	1,874,027	3.7	1,025,945	3.6	192,259	7.1	32,132	7.1	9,545	19.1	2,144	5.5	998	4.8	265	5.8
Urinary tract infection	582,580	1.2	475,872	1.7	155,228	5.7	24,518	5.4	4,186	8.4	1,513	3.9	802	3.9	233	5.1
Reduced libido/sexual dysfunction	251,761	0.5	113,464	0.4	48,447	1.8	5,063	1.1	1,646	3.3	925	2.4	382	1.8	136	3.0

MEDICATIONS PRESCRIBED (2024 ONLY)																
Any antihypertensives	7,517,140	14.9	3,989,735	14.1	910,449	33.6	173,461	38.2	20,548	41.0	11,395	29.1	6,704	32.4	1,215	26.5
Diuretics	3,517,551	7.0	1,970,531	7.0	447,095	16.5	82,670	18.2	10,225	20.4	5,958	15.2	3,540	17.1	650	14.2
Calcium channel blockers	3,193,102	6.3	1,680,663	6.0	375,356	13.8	73,721	16.3	8,571	17.1	4,459	11.4	2,658	12.8	465	10.1
Angiotensin receptor blockers (ARBs)	2,620,231	5.2	1,378,591	4.9	367,216	13.5	54,284	12.0	16,971	33.9	4,443	11.4	2,534	12.2	661	14.4
Angiotensin-converting enzyme (ACE) inhibitors	2,200,497	4.4	1,007,834	3.6	249,173	9.2	72,756	16.0	7,854	15.7	4,440	11.4	2,429	11.7	424	9.2
Beta blockers	166,855	0.3	88,731	0.3	18,832	0.7	47,734	10.5	5,463	10.9	3,029	7.7	1,734	8.4	284	6.2
Selective serotonin reuptake inhibitors (SSRIs)	2,881,029	5.7	1,979,170	7.0	334,126	12.3	57,221	12.6	12,059	24.1	14,230	36.4	7,290	35.2	1,570	34.2
Hormonal therapies	2,184,875	4.3	2,143,796	7.6	501,800	18.5	31,518	6.9	6,986	13.9	3,951	10.1	1,660	8.0	383	8.3
GLP-1 receptor agonists	1,517,046	3.0	978,713	3.5	210,823	7.8	21,578	4.8	8,407	16.8	1,432	3.7	891	4.3	276	6.0
Sleep medications	997,381	2.0	594,097	2.1	126,453	4.7	16,699	3.7	6,490	13.0	1,270	3.2	724	3.5	181	3.9
Serotonin norepinephrine reuptake inhibitors (SNRIs)	620,040	1.2	432,049	1.5	96,567	3.6	17,473	3.9	3,180	6.3	1,168	3.0	1,258	6.1	243	5.3
Medications for urinary incontinence	508,249	1.0	313,988	1.1	97,455	3.6	68,216	15.0	3,648	7.3	854	2.2	579	2.8	230	5.0
Osteoporosis medications	476,663	0.9	422,484	1.5	171,083	6.3	3,174	0.7	600	1.2	217	0.6	107	0.5	19	0.4
Weight-loss medications	40,279	0.1	33,605	0.1	6,881	0.3	764	0.2	220	0.4	156	0.4	59	0.3	17	0.4
Medications for hot flashes	11,571	<0.1	11,465	<0.1	8,309	0.3	1,063	0.2	273	0.5	208	0.5	152	0.7	73	1.6
PROCEDURES (2020-2024)																
Bone mineral density tests	2,288,071	4.6	2,034,148	7.2	1,122,797	41.4	453,647	100	20,351	40.6	7,404	18.9	3,855	18.6	1,200	26.1
Behavioral health intervention	1,615,104	3.2	1,001,883	3.6	118,458	4.4	18,289	4.0	50,079	100	1,935	4.9	769	3.7	228	5.0
Endometrial biopsy	299,420	0.6	299,206	1.1	144,230	5.3	12,400	2.7	3,546	7.1	39,116	100	7,029	34.0	643	14.0
Hysterectomy	223,187	0.4	221,824	0.8	81,607	3.0	7,496	1.7	1,652	3.3	4,612	11.8	20,695	100	698	15.2
Salpingo-oophorectomy/oophorectomy	98,362	0.2	98,168	0.3	19,943	0.7	2,501	0.6	547	1.1	591	1.5	706	3.4	4,589	100

¹Total includes 75 partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Denominator for percentage is the count for all female patients with menopausal conditions.

⁴Menopausal and other perimenopausal disorders include the following conditions based on ICD-10 codes: menopausal climacteric states (N95.1), postmenopausal atrophic vaginitis (N95.2), postmenopausal bleeding (N95.0), other menopausal and peri-menopausal disorders (N95.8), and unspecified menopausal and peri-menopausal disorders (N95.9).